Ray Dalio Cure Vac N.V. Transaction History
Bridgewater Associates, LP
- $23.8 Billion
- Q3 2025
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Cure Vac N.V. stock. As of the latest transaction made, Bridgewater Associates, LP holds 466,407 shares of CVAC stock, worth $2.46 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
466,407Holding current value
$2.46 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CVAC
# of Institutions
108Shares Held
22.5MCall Options Held
124KPut Options Held
77.1K-
Glazer Capital, LLC New York, NY4.55MShares$24 Million0.82% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ2.3MShares$12.1 Million0.78% of portfolio
-
Black Rock Inc. New York, NY2.25MShares$11.9 Million0.0% of portfolio
-
Qube Research & Technologies LTD London, X01.71MShares$9.04 Million0.01% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$8.28 Million10.6% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $990M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...